Get the Stockscreener App
3.02
3.07%
0.09
Neumora Therapeutics Inc stock is traded at $3.02, with a volume of 4.56M.
It is up +3.07% in the last 24 hours and up +65.93% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$2.93
Open:
$3
24h Volume:
4.56M
Relative Volume:
3.52
Market Cap:
$489.08M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-1.1915
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+14.83%
1M Performance:
+65.93%
6M Performance:
+287.28%
1Y Performance:
-73.62%
1-Day Range:
$2.82
$3.25
1-Week Range:
$2.40
$3.25
52-Week Range:
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.02 | 474.50M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - simplywall.st
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Is Neumora Therapeutics Inc. stock entering bullish territoryJuly 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 2025July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Neumora Therapeutics Inc. stock outlook for YEARJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
What risks investors should watch in Neumora Therapeutics Inc. stockWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
How moving averages guide Neumora Therapeutics Inc. trading2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryExit Point & AI Driven Price Predictions - newser.com
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora to initiate phase 1 study of oral obesity pill - MSN
Published on: 2025-10-30 01:21:45 - newser.com
What momentum shifts mean for Neumora Therapeutics Inc.2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - Fundação Cultural do Pará
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $18 - 富途牛牛
Needham Maintains Neumora Therapeutics (NMRA) Buy Recommendation - Nasdaq
Why hedge funds are buying Neumora Therapeutics Inc. stock2025 Market Trends & Weekly Top Gainers Alerts - Fundação Cultural do Pará
Real time social sentiment graph for Neumora Therapeutics Inc.2025 Top Gainers & Verified Entry Point Signals - newser.com
Published on: 2025-10-30 01:45:00 - newser.com
Will Neumora Therapeutics Inc. stock reach Wall Street targetsEarnings Recap Summary & Weekly Hot Stock Watchlists - Fundação Cultural do Pará
Neumora initiates phase 1 study of second M4 PAM compound By Investing.com - Investing.com Philippines
How Neumora Therapeutics Inc. stock valuations compare to rivalsPortfolio Return Report & Free Safe Entry Trade Signal Reports - Fundação Cultural do Pará
Neumora’s obesity drug shows up to 26% weight loss in preclinical studies - Investing.com Canada
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - TipRanks
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - TipRanks
Neumora initiates phase 1 study of second M4 PAM compound - Investing.com
How Neumora Therapeutics Inc. stock performs after earnings2025 Key Highlights & Free Community Consensus Stock Picks - Fundação Cultural do Pará
Is Neumora Therapeutics Inc. stock positioned well for digital economyJuly 2025 Movers & Low Risk High Reward Trade Ideas - Fundação Cultural do Pará
Guggenheim upgrades Neumora Therapeutics stock to Buy on obesity data By Investing.com - Investing.com Nigeria
Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics - TipRanks
Neumora’s obesity drug shows up to 26% weight loss in preclinical studies By Investing.com - Investing.com South Africa
Will Neumora Therapeutics Inc. stock split again soon2025 Risk Factors & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):